The Food and Drug Administration on Thursday approved Merck's antiviral drug Prevymis to prevent cytomegalovirus infections in patients after a stem cell transplant, reports Reuters.
Here are three things to know.
1. The agency approved Prevymis as both a tablet, which will cost $195 per day, and as an infection, which will cost $270 per day.
2. The drug's recommended dosing is once-daily for 100 days after the stem cell transplant.
3. Merck plans to launch Prevymis in December.
More articles on supply chain:
Sens. Chuck Grassley, Elizabeth Warren ask CMS to clarify position on unique device identifiers by Dec. 1
Indiana claims Nantworks failed to fulfill promises to state, seeks $1.4M
7 must-reads for supply chain leaders this week